Background. The effect of ranolazine (RAN) on cardiac autonomic balance in congestive heart failure (CHF) was studied. Methods. Fifty-four CHF patients were randomized to (1) open-label RAN (RANCHF) added to usual therapy vs. (2) usual therapy (NORANCHF). Parasympathetic and sympathetic (P&S) measurements were taken at baseline and at 12 months. Results. A total of 16/27 (59%) patients in both groups had initially abnormal P&S measures, including high sympathovagal balance (SB), cardiovascular autonomic neuropathy (CAN) or both. High SB normalized in 10/12 (83%) RANCHF patients vs. 2/11 (18%) NORANCHF patients. SB became high in 5/11 (45%) NORANCHF vs. 1/11 (9%) RANCHF patients. CAN improved in 4/6 (67%) RANCHF patients vs. 5/7 (45%) NORANCHF patients. CAN developed in 1/11 (9%) RANCHF vs. 4/11 (36%) NORANCHF patients. Since improved P&S in RANCHF patients seemed independent of improved brain natriuretic peptide and impedance cardiography (BioZ) measurements, 5 day RAN was given to 30 subjects without CHF but with high SB or CAN. P&S improved in 90% of these subjects. Conclusions. RAN improves unfavorable P&S activity in CHF possibly by a direct effect upon autonomic sodium channels.
Cardiovascular autonomic neuropathy, Congestive heart failure, Major adverse cardiac events, Parasympathetic function, Patient outcomes, Ranolazine, Sympathetic function
Financial support: No grants or funding have been received for this
Related Content In Heart failure
Quantification of Seasonal Variation in Daily Physical Activity in Individuals with Heart Failure and Implantable Cardioverter Defibrillator/Cardiac Resynchronisation Therapy Devices
Heart International. 2019;13(2):31–7
In individuals with heart failure (HF) who also have implanted cardioverter defibrillators and/or cardiac resynchronisation therapy (ICD/CRT) devices, low daily physical activity (PA) levels lead to increased risk of mortality, poor aerobic capacity and lower health-related quality of life.1 Improving daily PA in these individuals may, therefore, be an important clinical endpoint; however, designing interventional […]
Normalised Heart Rate Variability After Sacubitril/Valsartan
European Journal of Arrhythmia & Electrophysiology. 2019;5(1):60-1 DOI: https://doi.org/10.17925/EJAE.2019.5.1.60
We report the case of a 44-year-old woman with a history of chronic heart failure with reduced ejection fraction (HFrEF) due to ischemic cardiomyopathy (New York Heart Association [NYHA] class II). In 2010, she had a myocardial infarction with thrombotic occlusion of the left anterior descending coronary artery, alleged in the context of an essential thrombocythaemia. […]
Electronic and Mobile Health in Chronic Heart Failure
European Journal of Arrhythmia & Electrophysiology. 2018;4(2):45–6 DOI: https://doi.org/10.17925/EJAE.2018.4.2.45
In recent years, there has been increasing realisation that electronic health (e-health) – an umbrella term for multiple approaches to using information and communication technologies in health care – can encourage optimised and personalised delivery of care.1 Effective e-health initiatives may have benefits for both patient outcomes – through better education, information and self-management – […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!